Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

Abstract

Ixekizumab had an acceptable safety profile with no unexpected safety findings during ixekizumab maintenance in psoriasis.

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

“…This finding was expected and is in alignment with longer-term IXE studies in patients with plaque psoriasis 27 . The AIESP safety analysis, including safety data from all 52 weeks of this study, demonstrated safety and tolerability consistent with the known safety profile of IXE.…”

Rethinking of Small Molecules in Treating Psoriasis

“…Consequently, these treatments suffer from long-term disadvantages including severe side effects (induction of cancer and infections because of completely blocking physiological functions of IL-17 or IL-23), and critically when the treatments stop, all disease symptoms will not only immediately rebound back, but the disease conditions will often get much worse as balance of your immune system becomes deleterious, it do occur clinically (personal communications). The observed development of ulcerative colitis and Crohn during ixekizumabe trial [11,12] is another good example of deleterious immune system by the biologic.…”

“…Indeed, various infections have been observed clinically, which include, but are not limited to, infections of the upper respiratory tract and TB [11,12]. It has been also reported that Ixekizumab induces nonmelanoma skin cancers (NMSC), and inflammatory bowel diseases (both ulcerative colitis and Crohn's disease) -another good example of imbalanced immune system worsening.…”

“…It has been also reported that Ixekizumab induces nonmelanoma skin cancers (NMSC), and inflammatory bowel diseases (both ulcerative colitis and Crohn's disease) -another good example of imbalanced immune system worsening. Evaluation of long term therapeutic benefits and risk (pharmacovigilance) of biologic drugs is warranted [11,12].…”

“…They are all biologics as antibodies either against IL-17 antibody, such as ixekizumab from Eli Lilly or against IL-23, such as guselkumab from Johnson & Johnson, or other proinflammatory cytokines. It appears these new drugs are effective and tolerable in short run [11,12]; long term pharmacovigilance, however, is warranted.…”